Lipoic acid

ApprovedSmall molecule

Lipoic acid is one of 224 small molecule programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

223

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruiting

Peripheral NeuropathyActive, not recruiting

Oxidative StressActive, not recruiting

Multiple SclerosisActive, not recruiting

Type 2 DiabetesActive, not recruiting

Optic NeuritisActive, not recruiting

Secondary Progressive Multiple SclerosisActive, not recruiting

PolyneuropathyActive, not recruiting

NeuropathyActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 2

Active, not recruiting

Peripheral NeuropathyPhase 1/Phase 2

Active, not recruiting

Oxidative StressPhase 2

Active, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

Optic NeuritisPhase 1

Active, not recruiting

Secondary Progressive Multiple SclerosisPhase 2/Phase 3

Active, not recruiting

PolyneuropathyPhase 2/Phase 3

Active, not recruiting

NeuropathyApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Lipoic acid

NNovaMed Pharmaceuticals Inc.

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Aurlumyn

BBTG International Inc.

Preclinical

1 6

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 7

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 8

Forxiga

AstraZeneca

Preclinical

3 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Sclerosis2 trials

A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

Completed·OOregon Health and Science University·Phase 1·NCT00676156·40 enrolled

Lipoic Acid for Progressive Multiple Sclerosis (MS)

Completed·VVA Office of Research and Development·Phase 2·NCT03161028·115 enrolled

Type 2 Diabetes1 trial

The Effects of Lipoic Acid on Glycaemic Control in Type 2 Diabetes

Withdrawn·UUniversity of Edinburgh·Phase 2·NCT00398892

Polyneuropathy1 trial

Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy

Unknown status·NNovaMed Pharmaceuticals Inc.·Phase 2/3·NCT01224353·200 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

Completed·OOregon Health and Science University·Phase 2·NCT00962429·7 enrolled

Optic Neuritis1 trial

Lipoic Acid as a Treatment for Acute Optic Neuritis

Completed·OOregon Health and Science University·Phase 1·NCT01294176·31 enrolled

5 more indications

Peripheral Neuropathy1 trial

Treatment With Human Umbilical Cord Mesenchymal Stem Cells for Refractory Diabetic Peripheral Neuropathy

Unknown status·—·Phase 1/2·NCT05507697·42 enrolled

Function1 trial

Antioxidant Functions of Lipoic Acid

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00065624·16 enrolled

Secondary Progressive Multiple Sclerosis1 trial

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

Completed·VVA Office of Research and Development·Phase 2/3·NCT01188811·54 enrolled

Neuropathy1 trial

The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy

Completed·TThe Catholic University of Korea·Phase 4·NCT02056366·91 enrolled

Oxidative Stress1 trial

A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants

Completed·—·Phase 2·NCT01495260·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lipoic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lipoic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lipoic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NovaMed Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNovaMed Pharmaceuticals Inc.

Lipoic acid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Sclerosis2 trials

Type 2 Diabetes1 trial

Polyneuropathy1 trial

Chronic Inflammatory Demyelinating Polyneuropathy1 trial

Optic Neuritis1 trial

Peripheral Neuropathy1 trial

Function1 trial

Secondary Progressive Multiple Sclerosis1 trial

Neuropathy1 trial

Oxidative Stress1 trial

References

Drug Info

Quick Facts

Related News